MedTrace Logo

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2022-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.

Conditions

Interventions

BIOLOGICAL

Placebo

Placebo administered subcutaneously

BIOLOGICAL

Brodalumab

Brodalumab administered subcutaneously

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-22
Primary Completion
2015-05-15
Completion
2015-05-15

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • Greece
  • Hong Kong
  • Ireland
  • Italy
  • New Zealand
  • Poland
  • Puerto Rico
  • Russia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01902290 on ClinicalTrials.gov